Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient

US9434822B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9434822-B2
Application numberUS-201313971036-A
CountryUS
Kind codeB2
Filing dateAug 20, 2013
Priority dateSep 22, 2004
Publication dateSep 6, 2016
Grant dateSep 6, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A medicinal preparation is desired which has no harmful side effects such as hypersensitive reaction, heightens the water solubility of a sparingly water-soluble anticancer agent, maintains a high drug concentration in the blood, accumulates a drug in a tumor tissue at a high concentration, heightens the pharmacological effect of the sparingly water-soluble anticancer agent, and diminishes the side effects of the anticancer agent. Provided are: a novel block copolymer which can be a drug carrier having no harmful side effects such as hypersensitive reaction; a micelle preparation in which micelles are formed and which contains a sparingly water-soluble anticancer agent, especially paclitaxel, incorporated in the micelles in an amount necessary for a disease treatment without bonding it to the block copolymer and which can heighten the solubility of the drug in water; and an anticancer agent which comprises the micelle preparation as a medical ingredient, maintains a high concentration in the blood, has more potent drug activity, and is reduced in toxicity.

First claim

Opening claim text (preview).

What is claimed is: 1. A block copolymer represented by the following general formula (3): wherein R1 represents a hydrogen atom or a (C1 to C5) alkyl group, R2 represents a (C1 to C5) alkylene group, R3 represents a methylene group or an ethylene group, R4 represents a hydrogen atom or a (C1 to C4) acyl group, R5 represents a hydroxyl group, an optionally substituted aryl (C1 to C8) alkoxy group or —N(R6)-CO—NHR7, R6 and R7 may be the same or different and each represents a (C3 to C6) cyclic alkyl group or a (C1 to C5) alkyl group optionally substituted with a tertiary amino group; n represents 5 to 1000, m represents 2 to 300, x′ represents 0 to 300 and y′ represents 0 to 300, provided that the sum of x′ and y′ is 1 or and less than m; and R5 is a hydroxyl group at a ratio 0% relative to m, an optionally substituted aryl (C1 to C8) alkoxy group at a ratio of 10-80% relative to m, and —N(R6)-CO—NHR7 at a ratio of 11-30% relative to m. 2. The block copolymer according to claim 1 , wherein R1 is a methyl group, R2 is a trimethylene group, R3 is a methylene group, R4 is an acetyl group, the optionally substituted aryl (C1 to C8) alkoxy group represented by R5 is a benzyloxy group or a 4-phenyl-1-butoxy group, each of R6 and R7 is an isopropyl group, n is 20 to 500, m is 10 to 100, x′ is 0 to 100, and y′ is 0 to 100. 3. A micelle preparation formed from the block copolymer of claim 1 or 2 and a sparingly water-soluble anticancer agent. 4. The micelle preparation according to claim 3 , wherein the sparingly water-soluble anticancer agent is a taxane-based anticancer agent. 5. The micelle preparation according to claim 4 , wherein the taxane-based anticancer agent is paclitaxel. 6. An anticancer agent comprising the micelle preparation of claim 3 as an active ingredient and a pharmacologically acceptable additive. 7. An anticancer agent comprising the micelle preparation of claim 4 as an active ingredient and a pharmacologically acceptable additive. 8. An anticancer agent comprising the micelle preparation of claim 5 as an active ingredient and a pharmacologically acceptable additive.

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • having four-membered rings, e.g. taxol · CPC title

  • C08G81/00Primary

    Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers (involving only carbon-to-carbon unsaturated bond reactions C08F299/00 {; polyester-amides C08G69/44; polyester-imides C08G73/16; polyamides-imides C08G73/14; block- or graft polymers containing polysiloxane sequences C08G77/42}) · CPC title

  • A61K9/1075Primary

    Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title

  • Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9434822B2 cover?
A medicinal preparation is desired which has no harmful side effects such as hypersensitive reaction, heightens the water solubility of a sparingly water-soluble anticancer agent, maintains a high drug concentration in the blood, accumulates a drug in a tumor tissue at a high concentration, heightens the pharmacological effect of the sparingly water-soluble anticancer agent, and diminishes the …
Who is the assignee on this patent?
Nippon Kayaku Kk
What technology area does this patent fall under?
Primary CPC classification C08G81/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).